$EMED
Electromedical Technologies, Inc Stock $emed

$emed Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000141057824000581 Filed on May 01, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$237.6K	$351.6K	$1.349M
YoY Change	-19.43%	-16.91%	17.3%
Cost Of Revenue	$64.39K	$80.65K	$303.3K
YoY Change	2.99%	-10.61%	16.12%
Gross Profit	$173.3K	$271.0K	$1.046M
YoY Change	-25.46%	-18.62%	17.65%
Gross Profit Margin	72.9%	77.06%	77.51%
Selling, General & Admin	$425.1K	$493.9K	$3.110M
YoY Change	-25.92%	-15.54%	24.81%
% of Gross Profit	245.36%	182.29%	297.51%
Research & Development			$231.4K
YoY Change			150.74%
% of Gross Profit			22.14%
Depreciation & Amortization	$0.00	$0.00	$4.557K
YoY Change		-100.0%	-79.17%
% of Gross Profit	0.0%	0.0%	0.44%
Operating Expenses	$425.1K	$493.9K	$3.342M
YoY Change	-25.92%	-16.32%	29.31%
Operating Profit	-$251.8K	-$223.0K	-$2.065M
YoY Change	-26.23%	-13.35%	28.77%
Interest Expense	$58.30K	-$115.1K	$893.2K
YoY Change	-79.51%	-59.0%	12.9%
% of Operating Profit
Other Income/Expense, Net	$483.1K	-$19.00K	-$576.3K
YoY Change	-143.19%		-69.1%
Pretax Income	$231.2K	-$348.7K	-$2.641M
YoY Change	-115.84%	-58.0%	-23.85%
Income Tax
% Of Pretax Income
Net Earnings	$231.2K	-$348.7K	-$2.641M
YoY Change	-115.84%	-59.21%	-23.85%
Net Earnings / Revenue	97.3%	-99.16%	-195.82%
Basic Earnings Per Share	$0.00		$0.00
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	507.3M	463.1M	377.2M
Diluted Shares Outstanding	1.944B		377.2M

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$116.9K	$87.70K	$87.70K
YoY Change	-71.91%	-76.2%	-76.2%
Cash & Equivalents	$116.9K	$87.70K	$87.70K
Short-Term Investments
Other Short-Term Assets	$236.3K	$288.6K	$288.6K
YoY Change	-27.7%	38.82%	38.82%
Inventory	$31.68K	$68.52K	$68.52K
Prepaid Expenses
Receivables	$4.338K	$4.399K	$4.400K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$389.2K	$449.2K	$449.2K
YoY Change	-55.87%	-30.66%	-30.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$149.7K	$149.7K	$299.2K
YoY Change	0.0%	-78.78%	-57.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$275.7K	$299.2K	$299.2K
YoY Change	84.19%	-57.59%	-57.59%
TOTAL ASSETS
Total Short-Term Assets	$389.2K	$449.2K	$449.2K
Total Long-Term Assets	$275.7K	$299.2K	$299.2K
Total Assets	$665.0K	$748.4K	$748.4K
YoY Change	-35.55%	-44.7%	-44.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$240.4K	$239.5K	$267.6K
YoY Change	-10.81%	-10.22%	-12.09%
Accrued Expenses	$612.4K	$38.47K	$965.7K
YoY Change	-7.71%	-80.16%	-9.36%
Deferred Revenue	$438.2K	$197.3K
YoY Change	84.38%	-9.31%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.539M	$1.394M	$1.394M
YoY Change	8.94%	4.25%	4.25%
Total Short-Term Liabilities	$3.831M	$3.357M	$3.357M
YoY Change	21.48%	14.79%	14.79%
LONG-TERM LIABILITIES
Long-Term Debt	$150.0K	$150.0K	$150.0K
YoY Change	0.0%	-76.55%	-76.55%
Other Long-Term Liabilities	$4.982K	$8.416K	$114.6K
YoY Change	-50.17%	-17.76%	1020.43%
Total Long-Term Liabilities	$4.982K	$8.416K	$264.6K
YoY Change	-50.17%	-17.76%	-59.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.831M	$3.357M	$3.357M
Total Long-Term Liabilities	$4.982K	$8.416K	$264.6K
Total Liabilities	$4.065M	$3.621M	$3.621M
YoY Change	22.67%	1.32%	1.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$28.07M	-$27.47M
YoY Change	4.97%	10.65%
Common Stock	$5.659K	$4.631K
YoY Change	30.9%	144.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.400M	-$2.873M	-$2.873M
YoY Change
Total Liabilities & Shareholders Equity	$665.0K	$748.4K	$748.4K
YoY Change	-35.55%	-44.7%	-44.7%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$231.2K	-$348.7K	-$2.641M
YoY Change	-115.84%	-59.21%	-23.85%
Depreciation, Depletion And Amortization	$0.00	$0.00	$4.557K
YoY Change		-100.0%	-79.17%
Cash From Operating Activities	$108.9K	-$50.94K	-$1.417M
YoY Change	-117.13%	53.9%	83.28%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$149.7K
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	$1.895M
YoY Change
Cash From Investing Activities		$0.00	$1.745M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-70.84K	180.0	-608.2K
YoY Change	113.76%	-100.31%	-180.18%
NET CHANGE
Cash From Operating Activities	108.9K	-50.94K	-1.417M
Cash From Investing Activities		0.000	1.745M
Cash From Financing Activities	-70.84K	180.0	-608.2K
Net Change In Cash	38.09K	-50.76K	-280.7K
YoY Change	-104.65%	-43.91%	1803.84%
FREE CASH FLOW
Cash From Operating Activities	$108.9K	-$50.94K	-$1.417M
Capital Expenditures		$0.00	$149.7K
Free Cash Flow		-$50.94K	-$1.567M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001715819
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Registrant Name EntityRegistrantName	Electromedical Technologies, Inc
CY2023	dei	Security Exchange Name SecurityExchangeName	NONE
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2644707
CY2023	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://electromedtech.com/20231231#ChangeInFairValueOfDerivativeLiabilities
CY2023	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://electromedtech.com/20231231#ChangeInFairValueOfDerivativeLiabilities
CY2023Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#CommitmentsAndContingencies
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-56192
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2619815
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	16413 N. 91st Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ste. C140
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Scottsdale
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	AZ
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	85260
CY2023	dei	City Area Code CityAreaCode	888
CY2023	dei	Local Phone Number LocalPhoneNumber	880-7888
CY2023	dei	Security12b Title Security12bTitle	$0.00001 par value, common stock
CY2023	dei	Trading Symbol TradingSymbol	EMED
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	313166
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	507288394
CY2023	dei	Auditor Name AuditorName	dbbmckennon
CY2023	dei	Auditor Firm AuditorFirmId	3501
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87704
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	368425
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4399
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9444
CY2023Q4	us-gaap	Inventory Net InventoryNet	68517
CY2022Q4	us-gaap	Inventory Net InventoryNet	62061
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	288565
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	207872
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1149844
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	303303
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	261203
CY2023	us-gaap	Gross Profit GrossProfit	1045505
CY2022	us-gaap	Gross Profit GrossProfit	888641
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3110446
CY2023Q4	us-gaap	Assets Current AssetsCurrent	449185
CY2022Q4	us-gaap	Assets Current AssetsCurrent	647802
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	149493
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	149705
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	705469
CY2023Q4	us-gaap	Assets Assets	748383
CY2022Q4	us-gaap	Assets Assets	1353271
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	239481
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	266744
CY2023Q4	elcq	Credit Cards Payable CreditCardsPayable	28097
CY2022Q4	elcq	Credit Cards Payable CreditCardsPayable	37633
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	916971
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1065483
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	197325
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	217588
CY2023Q4	elcq	Discount On Convertible Promissory Notes Current DiscountOnConvertiblePromissoryNotesCurrent	0
CY2022Q4	elcq	Discount On Convertible Promissory Notes Current DiscountOnConvertiblePromissoryNotesCurrent	375865
CY2023Q4	elcq	Convertible Promissory Notes Payable Current ConvertiblePromissoryNotesPayableCurrent	1393601
CY2022Q4	elcq	Convertible Promissory Notes Payable Current ConvertiblePromissoryNotesPayableCurrent	1304909
CY2022Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	31818
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	48745
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	532334
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3356554
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2924175
CY2022Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	489707
CY2023Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	150000
CY2022Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	150000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	106200
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8416
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	10234
CY2023Q4	us-gaap	Liabilities Liabilities	3621170
CY2022Q4	us-gaap	Liabilities Liabilities	3574116
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1999000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	999000000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	463286208
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	189784529
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4631
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1896
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23827330
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22237300
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27469748
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24825041
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2872787
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2220845
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	748383
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1353271
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1348808
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2064941
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1603528
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2492169
CY2023	us-gaap	Interest Expense InterestExpense	893155
CY2022	us-gaap	Interest Expense InterestExpense	791072
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1193676
CY2023	elcq	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	120610
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-355597
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	409000
CY2022	elcq	Debt Instrument Forgiveness Of Debt DebtInstrumentForgivenessOfDebt	-5900
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	8381
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1079800
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-576305
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1864972
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2641246
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3468500
CY2023	elcq	Deemed Dividend Related To Warrant Resets DeemedDividendRelatedToWarrantResets	3461
CY2022	elcq	Deemed Dividend Related To Warrant Resets DeemedDividendRelatedToWarrantResets	107888
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3576388
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	377216319
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	377216319
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133596295
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133596295
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-722503
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	42766
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	494900
CY2022	elcq	Stock Issued During Period Value In Conjunction Forbearance Of Convertible Debt StockIssuedDuringPeriodValueInConjunctionForbearanceOfConvertibleDebt	142800
CY2022	elcq	Share Issued During Period Value Convertible Promissory Notes Settlement ShareIssuedDuringPeriodValueConvertiblePromissoryNotesSettlement	708370
CY2022	elcq	Adjustments To Additional Paid In Capital Warrant Issued In Conjunction With Debt Settlement AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConjunctionWithDebtSettlement	65000
CY2022	elcq	Adjustments To Additional Paid In Capital Warrants Issued In Conjunction With Convertible Promissory Notes AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConjunctionWithConvertiblePromissoryNotes	445974
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	435000
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14703
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3468500
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2220845
CY2023	elcq	Stock Issued During Period Value Conversion Of Convertible Securities Accrued Interest And Derivative Liabilities StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesAccruedInterestAndDerivativeLiabilities	300034
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	400000
CY2023	elcq	Share Issued During Period Values In Conjunction Settlement Reset ShareIssuedDuringPeriodValuesInConjunctionSettlementReset	698000
CY2023	elcq	Share Issued During Period Values In Settlement Of Stock Based Compensation Liabilities ShareIssuedDuringPeriodValuesInSettlementOfStockBasedCompensationLiabilities	21000
CY2023	elcq	Stock Issued During Period Value Warrant Exercises For Cash StockIssuedDuringPeriodValueWarrantExercisesForCash	175
CY2023	elcq	Adjustments To Additional Paid In Capital Valuation Of Trigger Warrants AdjustmentsToAdditionalPaidInCapitalValuationOfTriggerWarrants	263476
CY2023	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	8381
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2641246
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2872787
CY2023	us-gaap	Profit Loss ProfitLoss	-2641246
CY2022	us-gaap	Profit Loss ProfitLoss	-3468500
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	715000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	509603
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1845
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4557
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21875
CY2023	elcq	Right Of Use Asset Amortization RightOfUseAssetAmortization	21648
CY2022	elcq	Forgiveness Of Debt Instrument ForgivenessOfDebtInstrument	5900
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	8381
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1079800
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	639341
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	584261
CY2023	elcq	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	120610
CY2023	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	355597
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1193676
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	876
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3200
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-25641
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6456
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-156449
CY2023	elcq	Prepaid Inventories And Other Current Asset PrepaidInventoriesAndOtherCurrentAsset	80693
CY2022	elcq	Prepaid Inventories And Other Current Asset PrepaidInventoriesAndOtherCurrentAsset	169870
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-27263
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	51959
CY2023	elcq	Increase Decrease In Credit Card Payables IncreaseDecreaseInCreditCardPayables	-9536
CY2022	elcq	Increase Decrease In Credit Card Payables IncreaseDecreaseInCreditCardPayables	26350
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	725461
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	196340
CY2023	elcq	Increase Decrease In Customer Deposits Operating Activities IncreaseDecreaseInCustomerDepositsOperatingActivities	-20263
CY2022	elcq	Increase Decrease In Customer Deposits Operating Activities IncreaseDecreaseInCustomerDepositsOperatingActivities	217588
CY2023	elcq	Increase Decrease In Financial Lease Liability IncreaseDecreaseInFinancialLeaseLiability	-16196
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-1818
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1067
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1417393
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-773337
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	149705
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1894588
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1744883
CY2023	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	522401
CY2022	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	25355
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-57875
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1545140
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	85985
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	746084
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	175
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	42766
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-608211
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	758592
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-280721
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14745
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	368425
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	383170
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87704
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	368425
CY2023	us-gaap	Interest Paid Net InterestPaidNet	40241
CY2022	us-gaap	Interest Paid Net InterestPaidNet	103819
CY2022	elcq	Adoption Of Accounting Standard AdoptionOfAccountingStandard	379355
CY2023	elcq	Settlement Of Stock Based Compensation Liabilities SettlementOfStockBasedCompensationLiabilities	719000
CY2022	elcq	Warrants Common Stock And Beneficial Conversion Feature Issued In Conjunction With Convertible Promissory Note WarrantsCommonStockAndBeneficialConversionFeatureIssuedInConjunctionWithConvertiblePromissoryNote	510974
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	300034
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1103370
CY2022Q4	us-gaap	Deferred Income DeferredIncome	23313
CY2022	elcq	Increase Decrease In Operating Loss Carryforwards IncreaseDecreaseInOperatingLossCarryforwards	214257
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5403695
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4090409
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.025
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	164408
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of certain assets and liabilities, certain disclosures at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates affecting the financial statements have been prepared based on the most current and best available information. However, actual results from the resolution of such estimates and assumptions may vary from those used in the preparation of the financial statements.</p>
CY2023	elcq	Accumulated Net Loss AccumulatedNetLoss	23700000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1417393
CY2023	elcq	Working Capital Deficit WorkingCapitalDeficit	2900000
CY2023	elcq	Right Of Return Period RightOfReturnPeriod	P30D
CY2022	elcq	Sales Returns Allowance SalesReturnsAllowance	6990
CY2023	elcq	Sales Returns Allowance SalesReturnsAllowance	6990
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	197325
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	217588
CY2023	elcq	Initial Warranty Period InitialWarrantyPeriod	P3Y
CY2023Q4	us-gaap	Deferred Income DeferredIncome	20787
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1845
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1000
CY2023Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	12442
CY2022Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	13342
CY2023Q4	us-gaap	Due From Customer Acceptances DueFromCustomerAcceptances	594
CY2022Q4	us-gaap	Due From Customer Acceptances DueFromCustomerAcceptances	0
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	70950
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	73385
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	491846
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	80122
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	120610
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	532334
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1260254
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	38465
CY2023Q4	elcq	Deferred Tax Accounts Payable DeferredTaxAccountsPayable	7061
CY2023Q4	elcq	Deferred Tax Assets Customer Deposits DeferredTaxAssetsCustomerDeposits	5248
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.259
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	326627
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	933627
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	263660
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	53288
CY2023	elcq	Increase Decrease In Operating Loss Carryforwards IncreaseDecreaseInOperatingLossCarryforwards	1313286
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21875
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1393601
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1680774
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	375865
CY2023Q4	us-gaap	Notes Payable NotesPayable	1393601
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	61000
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	61000
CY2023	elcq	Standard Warranty Period StandardWarrantyPeriod	P3Y
CY2023Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	16642
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	12679
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	0
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	231434
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	92299
CY2023Q4	elcq	Stock Options Warrants And Convertible Promissory Notes With Underlying Shares StockOptionsWarrantsAndConvertiblePromissoryNotesWithUnderlyingShares	1535713792
CY2022Q4	elcq	Stock Options Warrants And Convertible Promissory Notes With Underlying Shares StockOptionsWarrantsAndConvertiblePromissoryNotesWithUnderlyingShares	231796422
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	420000000
CY2022Q4	us-gaap	Notes Payable NotesPayable	1304909
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.025
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	174692
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	899987
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24987
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	194518
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	149705
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	705469
CY2023Q1	elcq	Net Proceeds From Sale Of Buildings Upon Repayment Of Bank Debt NetProceedsFromSaleOfBuildingsUponRepaymentOfBankDebt	1363818
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1193676
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4557
CY2023	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	932600
CY2023	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	93700
CY2023	elcq	Debt Default Penalty Amount DebtDefaultPenaltyAmount	257000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1393601
CY2023Q4	us-gaap	Notes Payable NotesPayable	1393601
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1680774
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	375865
CY2022Q4	us-gaap	Notes Payable NotesPayable	1304909
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1440
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	3246
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	145314
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	150000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	491846
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	80122
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	120610
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	532334
CY2022Q4	elcq	Number Of Members Appointed In Board NumberOfMembersAppointedInBoard	2
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	7500000
CY2022	elcq	Stock Issued During Period Value Per Share Issued For Services StockIssuedDuringPeriodValuePerShareIssuedForServices	0.035
CY2022	us-gaap	Stock Issued1 StockIssued1	262500
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	999000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1999000000
CY2023Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	2000000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	65271
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	67230
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	51548
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	184049
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	29104
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12000
CY2022Q2	elcq	Debt Conversion Converted Instrument Accrued Interest Amount DebtConversionConvertedInstrumentAccruedInterestAmount	51017
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	26734801
CY2022	elcq	Cashless Warrants Exercised CashlessWarrantsExercised	17249999
CY2022	elcq	Number Of Shares Issued Upon Exercise Of Warrants NumberOfSharesIssuedUponExerciseOfWarrants	13264887
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	350000
CY2022	elcq	Stock Issued During Period Shares Conversion Of Convertible Note And Notes Payable StockIssuedDuringPeriodSharesConversionOfConvertibleNoteAndNotesPayable	30500000
CY2022Q3	us-gaap	Share Price SharePrice	0.02
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	50000000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	173000000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	263476
CY2023	elcq	Adjustments To Additional Paid In Capital Warrants Reset AdjustmentsToAdditionalPaidInCapitalWarrantsReset	3461
CY2023	elcq	Stock Issued During Period Shares Warrant Exercises StockIssuedDuringPeriodSharesWarrantExercises	375000
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	176838431
CY2022	elcq	Warrants Issued WarrantsIssued	21000000
CY2022Q2	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	500000
CY2022Q2	elcq	Warrants Issued WarrantsIssued	2500000
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.025
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q2	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	65000
CY2022Q2	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	259000
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	27837533
CY2022	elcq	Reduction To Retained Earnings And Increase In Additional Paid In Capital ReductionToRetainedEarningsAndIncreaseInAdditionalPaidInCapital	107888
CY2023	elcq	Commitment For Product Development CommitmentForProductDevelopment	300000
CY2023	elcq	Amount For Commitment For Product Development Paid AmountForCommitmentForProductDevelopmentPaid	150000
CY2023	elcq	Expected Milestone Term ExpectedMilestoneTerm	P12M
CY2023Q3	elcq	Operating Lease Rental Payments OperatingLeaseRentalPayments	5280
CY2023Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2023Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.124
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	21648
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	154945
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	932600
CY2023	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	93700
CY2023Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	1.25
CY2023Q4	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	257000
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001410578-24-000581-index-headers.html	Edgar Link	pending
0001410578-24-000581-index.html	Edgar Link	pending
0001410578-24-000581.txt	Edgar Link	pending
0001410578-24-000581-xbrl.zip	Edgar Link	pending
elcq-20231231.xsd	Edgar Link	pending
elcq-20231231x10k.htm	Edgar Link	pending
elcq-20231231x10k001.jpg	Edgar Link	pending
elcq-20231231xex10d15.htm	Edgar Link	pending
elcq-20231231xex31d1.htm	Edgar Link	pending
elcq-20231231xex31d2.htm	Edgar Link	pending
elcq-20231231xex32d1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
elcq-20231231_cal.xml	Edgar Link	unprocessable
elcq-20231231_def.xml	Edgar Link	unprocessable
elcq-20231231_lab.xml	Edgar Link	unprocessable
elcq-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
elcq-20231231x10k_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EMED
Electromedical Technologies, Inc Stock $emed

2024 Q2 Form 10-K Financial Statement

#000141057824000581 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMED Electromedical Technologies, Inc Stock $emed

2024 Q2 Form 10-K Financial Statement

#000141057824000581 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMED
Electromedical Technologies, Inc Stock $emed